Study of Biomarkers in Gynecological Cancers (NCT03420118)
Molecular and Immunological Characterization of Gynecological Malignancies
๐ฉบ Plain-English Summary (8th-Grade Level)
In recent years, there has been a significant improvement in understanding the biology of cancer and this information has been used to improve cancer care and patient outcome. Research has shown that changes in some genes and/or proteins may be important indicators for certain cancers and response to treatments. Genes are molecules made up of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). DNA contain instructions for the development and functioning of the cells in the body and are passed down from parent to child. RNA is involved with producing proteins in the body. Further research is needed to better understand the changes found in cancer cells and how to target them to stop or reduce cancer growth. A drug that may be able to block certain specific cancer cell changes is called "targeted therapy". Different people with the same type of cancer receiving the same drug could have different responses to it. For example, one person may experience a reduction of their tumor while another person's cancer may worsen. The reason for this is still not well understood and could lie in gene changes. Understanding these changes may allow researchers to predict how treatments may work in guiding decisions around choice of drugs. The purpose of the study is to learn more about gene changes or protein expression (levels) of tumors to better understand the behavior of gynecological diseases and, if possible, better address participants' cancer care now or in the future.
Who can join: Review the eligibility criteria below.
Location: Princess Margaret Cancer Centre โ Toronto, Ontario
Age range: 18 Years
๐งช Interventions in This Study
- Tumour tissue collection (PROCEDURE)
- Blood draws (PROCEDURE)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Princess Margaret Cancer Centre โ Toronto, Ontario
๐ Contact the Study Coordinator
Phone: (416) 946-2818
Email: amit.oza@uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gynecologic Cancer
- Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer โ New Brunswick, New Jersey
- Patient Related Outcomes for Gynecologic Radiation Oncology โ Chapel Hill, North Carolina
- Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer โ Boston, Massachusetts
- Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention โ Houston, Texas
- Impact of Cultural and Linguistic Backgrounds on Patient Care and Experience of Women With Gynecologic Malignancies โ Toronto, Ontario
- Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer โ Minneapolis, Minnesota
Explore by condition: All Gynecologic Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.